Back

Wave launches Phase 2a WVE-007 obesity trial after preclinical data showed doubled weight loss

Verifying
  • Wave initiated a Phase 2a trial combining WVE-007 with weekly tirzepatide in adults with obesity.
  • WVE-007 will be tested at 240 mg and 400 mg doses in the combination study.
  • Wave plans a post-incretin maintenance trial in the second half of 2026.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.